Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist
Menée à partir des données GLOBOCAN 2020 et d'une revue de la littérature publiée entre 2010 et 2020, cette étude analyse l'association entre des caractéristiques du système national de santé de 148 pays, le stade de la maladie au diagnostic et la mortalité par cancer du sein
Disparities in cancer outcomes within and between countries have become increasingly more visible in the past two decades; some regions have achieved reductions both cancer incidence and mortality, whereas others are falling dramatically behind. In The Lancet Oncology, Catherine Duggan and colleagues report that 20 countries have achieved sustained mean reductions in breast cancermortality of at least 2% for 3 consecutive years since 1990, all of which are eitherhigh-income or upper-middle-income countries. All 20 of these countries with sustained mortality reductions had at least 60% of patients with breast cancer diagnosed atearly stages (stage I or II) of disease. In the multivariable analysis, the Universal Health Care Service Coverage Index score and number of public cancer centres per 10 000 patients with cancer were significantly and independently negatively associated withage-standardised mortality rates (
β=
–0·12, 95% CI −0·16 to −0·08, and
β=
–0·23, −0·36to −0·10, respectively). These results provide useful additional information on whichfuture research might be based.
The Lancet Oncology , commentaire, 2020